2 Novan execs out as company pushes to broaden focus
As Morrisville-based Novan (Nasdaq: NOVN) continues to execute on a broadened focus, the company is also seeing a pair of C-suite executives depart.
Novan said Thursday that it’s gotten underway with a Phase 2 clinical trial for its product candidate SB206 for the treatment of a viral skin infection known as molluscum, which falls in line with its previously announced pivot from a primary focus on acne to virology and immunology.
The clin ical trial announcement closely follows two filings with…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Jennifer Henderson Source Type: news
More News: Acne | Allergy & Immunology | Clinical Trials | Health Management | Pharmaceuticals | Skin | Virology